Here's a guestimate:
Variables to revenues etc:
- Some Febridx sales in rest of world could be attributed to the studies in Spain. That report indicated product was purchased direct from distributors and not supplied by Lumos.
- Uptake in US could show a higher increase in Febridx sales if rest of world remained steady at $75,000 a quarter based on last years info
- Viradx product varies between distributors with some providing the product for as low as $325 a box. Also currently sold via Wilburn Medical under by 5 get one free deal at $1875.
- Febridx price varies between provider also with some at $400 a box, some closer to $500 a box.
- Assuming other services revenue is consistent with previous years (around $8-$10Million annually) with increase for Hologic payment. They said the Hologic deal builds off the back of the existing services stuff they have done, so not sure of the $5M is in addition to existing revenue received from Hologic or combined with normal revenue.
Regarding SP at present, the overall market is down, so i wouldnt attribute the drop to quarterly news. I would attribute it to overall market sentiment.
All im my opinion and estimates - not to be taken as fact.
Add to My Watchlist
What is My Watchlist?
